CSL News: Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arct - 20th May 2024, 10:30pm

[annb0t]

Data follow the approval of the world’s first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster.

KING OF PRUSSIA, Pa. & SAN DIEGO, May 20, 2024--(BUSINESS WIRE)--Global biotechnology leader CSL (AS...

>>> Read more: Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine